AC Immune S.A. (ACIU) vs TriSalus Life Sciences, Inc. (TLSI)

A side-by-side comparison of AC Immune S.A. and TriSalus Life Sciences, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — ACIU vs TLSI

growth of $100 · dividends reinvested · last 6y
ACIU -62.3% (-15.0%/yr)TLSI -58.4% (-13.6%/yr)TLSI compounded faster over this window
20406080100120Start $10020222023202420252026$38$42
ACIU TLSI

ACIU vs TLSI: by the numbers

  • •TLSI is the larger company ($263M vs $256M market cap).
  • •Both run net losses; TLSI's is the smaller (-62.59% vs -249.94% net margin).

Metrics side by side

Valuation

MetricACIUTLSI
P/S ratio11.825.83
P/B ratio5.8940.14

Profitability

MetricACIUTLSI
Gross margin100.00%85.79%
Operating margin-1927.32%-59.68%
Net margin-249.94%-62.59%
ROE-124.67%-430.72%
ROIC-89.43%-59.50%

Growth (annualized)

MetricACIUTLSI
Revenue CAGR (5Y)-23.70%N/A
Total return CAGR (5Y)-16.03%-15.05%

Frequently asked

How have ACIU and TLSI total returns compared?
Over the past 5 years, ACIU delivered -16.03% and TLSI delivered -15.05% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.